Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia

  1. Pérez de Isla, L.
  2. Ray, K.K.
  3. Watts, G.F.
  4. Santos, R.D.
  5. Alonso, R.
  6. Muñiz-Grijalvo, O.
  7. Diaz-Diaz, J.L.
  8. Badimon, L.
  9. Catapano, A.L.
  10. Mata, P.
Revista:
Atherosclerosis

ISSN: 1879-1484,  0021-9150

Any de publicació: 2019

Volum: 286

Pàgines: 40-45

Tipus: Article

DOI: 10.1016/J.ATHEROSCLEROSIS.2019.05.003 GOOGLE SCHOLAR
Font de les dades: Scopus